Exclusive - Study Measures CBN vs Melatonin: The New Sleep Solution Showdown

FloraWorks Holdings, a cannabinoid therapeutics firm, has disclosed groundbreaking results from the first-ever double-blind, randomized, placebo-controlled trial for its prime offering, TruCBN, Benzinga Cannabis has learned exclusively. TruCBN is a pure form of Cannabinol (CBN), one among the extensive cannabinoid family in the cannabis plant. The trial, helmed by independent clinical research company Radicle Science, was designed to measure TruCBN's impact on sleep, in comparison with melatonin and a placebo.

Over 1,000 participants from across the U.S. formed the study group, receiving doses of TruCBN, melatonin, or a placebo. The findings from this novel study are remarkable:

  1. A significant sleep improvement was recorded in the cohort receiving a 50 mg dose of TruCBN, with most of the participants experiencing crucial enhancements.

  2. The melatonin group also exhibited notable sleep improvement.

  3. The 50 mg TruCBN group had slightly better sleep improvements than those on 4 mg of melatonin.

  4. Marginal sleep improvements were seen in the cohorts taking 25 mg and 100 mg of TruCBN.

  5. TruCBN demonstrated a U-shaped dose-response curve for sleep, with 50 mg delivering better sleep outcomes than either 25 mg or 100 mg.

  6. Side effects across all groups were minor or moderate, with no significant variation in their frequency between TruCBN and placebo groups.

FloraWorks CEO and co-founder, Alleh Lindquist, celebrates these findings, asserting, "Our results pave the way for developing more effective sleep solutions, ultimately improving the quality of life for millions of people who struggle with sleep disturbances." TruCBN is all set to challenge the established players in the global sleep aid market, satisfying consumers' clamor for CBN products and establishing faith in the therapeutic potential of cannabinoids.

Radicle Science's co-founder and CEO, Jeff Chen, MD/MBA, lauded the implications of the study's firsts, particularly the discovery of CBN's U-shaped dose-response curve. He stated that the research results will help to shape natural sleep products for Americans, emphasizing the need to get the dosage just right for effective results.

Dr. Susan Hewlings, PhD, RD, vice president of research affairs at Radicle Science, highlighted the significance of the findings in the context of recent FDA scrutiny towards melatonin dosage. She added that the results were "promising," considering that many people cannot tolerate the side effects of melatonin.

This scientific breakthrough is set to challenge the hegemony of over-the-counter sleep aids, as poor sleep, a public health concern linked to various health issues, plagues 60% of Americans. As the search for natural and safe alternatives grows, TruCBN, a non-intoxicating hemp-derived cannabinoid, presents a promising prospect. The results of this study may herald a shift in consumer preference towards natural alternative sleep aids like TruCBN, away from traditional sleep solutions.

Image: Canva, edited by Javier Hasse

Market News and Data brought to you by Benzinga APIs
Posted In: CannabisNewsExclusivesMarketscbnFloraWorks
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

The Benzinga Cannabis Capital Conference is coming to Florida

The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.

Get your tickets now on bzcannabis.com – Prices will increase very soon!